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Abstract 
Research and development of new drugs requires both long time and high costs, whereas safety and tolerability 
profiles make the success rate of approval very low. Drug repurposing, applying known drugs and compounds to 
new indications, has been noted recently as a cost-effective and time-unconsuming way in developing new drugs, 
because they have already been proven safe in humans. In this review, we discuss drug repurposing of approved 
cardiovascular drugs, such as aspirin, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor 
blockers, cardiac glycosides and statins. Regarding anti-tumor activities of these agents, a number of experimental 
studies have demonstrated promising pleiotropic properties, whereas all clinical trials have not shown expected 
results. In pathological conditions other than cancer, repurposing of cardiovascular drugs is also expanding. Numer-
ous experimental studies have reported possibilities of drug repurposing in this field and some of them have been 
tried for new indications (‘bench to bedside’), while unexpected results of clinical studies have given hints for drug 
repurposing and some unknown mechanisms of action have been demonstrated by experimental studies (‘bedside 
to bench’). The future perspective of experimental and clinical studies using cardiovascular drugs are also discussed.
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Background
Drug repurposing is a way to identify a new indication 
for existing drugs and compounds and is also called as 
drug repositioning, drug rescue or drug re-profiling. 
Drug repurposing generates lower costs and shorter time 
until approval than developing a drug de novo, because 
all phases of clinical trials have already performed for 
approved drugs and the information regarding side 
effects, pharmacokinetics and interaction with other 
drugs has been collected. Drug repurposing could also be 
useful for the treatment of rare or orphan diseases with-
out any proven treatments [1].
In this review, we discuss drug repurposing of approved 
cardiovascular drugs, such as aspirin, beta-blockers, 
angiotensin converting enzyme (ACE) inhibitors, angio-
tensin II receptor blockers (ARBs), cardiac glycosides 
and statins, which are commonly prescribed for the 
treatment and/or prevention of cardiovascular diseases. 
We focus on pleiotropic properties and action mecha-
nisms of each agent in tumor progression and metastasis. 
Aspirin not only prevents platelet function but also sup-
presses tumor cell proliferation directly. Beta-blockers 
inhibit tumor angiogenesis and invasiveness and induce 
apoptosis. ACE inhibitors and ARBs suppress tumor 
growth, angiogenesis and invasiveness. Pro-apoptotic 
activity of cardiac glycosides and anti-proliferative activ-
ity of statins are also described. Subsequently, we sum-
marize the findings of clinical studies investigating the 
relationship between cardiovascular drugs and cancer. 
Cancer-related events have not been included in the pri-
mary endpoints in most of the large-scale cardiovascular 
clinical trials, which makes it difficult to evaluate whether 
cardiovascular drugs really exhibit anti-tumor effects 
identified in experimental research. Nevertheless, aspirin 
and beta-blockers have advanced to randomized clinical 
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findings have been inconsistent with regard to cancer and 
ACE inhibitors, ARBs, cardiac glycosides or statins.
Repurposing of cardiovascular drugs is also expanding 
in pathological conditions other than cancer.
Numerous experimental studies have reported pos-
sibilities of drug repurposing in the cardiovascular field 
and some of them have been tried for new indications 
(‘bench to bedside’), whereas unexpected results of clini-
cal studies have given hints for drug repurposing and the 
unknown mechanisms of action have been demonstrated 
by experimental studies (‘bedside to bench’). The excel-
lent examples of drug repurposing are propranolol for 
infantile hemangioma, beta-blockers for migraine, pre-
operative statins for perioperative risk reduction and 
minoxidil for androgenic alopecia, which are prescribed 
in daily clinical practice. Beta-blockers might be effective 
for the treatment of cirrhosis and osteoporosis. RCTs are 
examining whether losartan and statins are effective for 
Marfan’s syndrome and contrast-induced nephropathy, 
respectively. In addition to the available knowledge, the 
future perspective of experimental and clinical studies 
using cardiovascular drugs are also discussed.
Repurposing of cardiovascular drugs in cancer
Aspirin and cancer
Aspirin is commonly used for the treatment and pre-
vention of atherosclerotic diseases, and pharmacologi-
cal targets of aspirin are two isoforms of cyclooxygenase 
(COX) enzyme, COX-1 and COX-2 [2]. COX-1 is a con-
stitutive enzyme expressed in most mammalian tissues 
and produces thromboxane A2 (TXA2) in platelets, 
which promotes platelets aggregation and adherence of 
platelets to tumor cells and thus prevents immune cells 
from recognizing and eliminating them, resulting in 
increased distant metastasis. On the other hand, COX-2 
is a rapidly inducible enzyme during inflammation and 
dominantly produces prostaglandin E2 (PGE2) in tumor 
cells compared with COX-1, and PGE2 is thought to 
play an important role in accelerating cell prolifera-
tion and tumor growth. Aspirin administered at low 
doses (50–100 mg daily) and high doses (>325 mg daily) 
selectively blocks COX-1 and COX-2 in an irreversible 
manner, respectively. The putative action mechanisms 
of aspirin in tumor progression and metastasis are dis-
played in Fig.  1. Since the anti-tumor effect of aspirin 
was first reported in tumor-bearing mice in 1972 [3, 
4], a number of subsequent experimental studies have 
supported this evidence [5]. As most clinical trials have 
shown a significant reduction in cancer risk and cancer-
associated death in patients taking aspirin at a low dose, 
but not a high dose [6, 7], one important mechanism of 
tumor suppression by aspirin is proposed as inhibition 
of COX-1. With this activity, low-dose aspirin could 
prevent platelets from binding to tumor cells, result-
ing in suppression of distant metastasis and improved 
survival. In addition, PGE2 was upregulated in colon 
cancer [8] and administration of PGE2 enhanced tumor 
growth and angiogenesis [9]. As PGE2 was significantly 
suppressed in human colons when aspirin was adminis-
tered even at a low dose (81 mg daily) [10], Suppression 
of PGE2 might be also important in anti-tumor activity 
of aspirin.
In clinical fields, a case–control study first demon-
strated that aspirin use was associated with reduced risk 
of CRC (colorectal cancer) (risk ratio (RR) 0.53, 95  % 
confidence interval [CI] 0.40–0.71, p  <  0.001) in 1988 
[11]. Since then, a number of observational studies have 


















Fig. 1 Putative mechanisms of action of low-dose aspirin in platelets and tumor cells in suppressing tumor growth. Low-dose aspirin exerts an 
inhibitory effect on platelet aggregation by suppressing production of TXA2 through inhibition of COX-1 in platelets. Thus, low-dose aspirin pre-
vents platelets from binding to tumor cells, resulting in suppression of distant metastasis. On the other hand, PGE2, which is upregulated in colon 
cancer cells, is suppressed by low-dose aspirin, leading to inhibition of tumor growth and angiogenesis. COX-1 cyclooxygenase-1, COX-2 cyclooxy-
genase-2, PGE2 prostaglandin E2, TXA2 thromboxane A2
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of several cancers including CRC [12], esophageal can-
cer [13], gastric cancer [13], breast cancer [13] and pros-
tate cancer [14–16]. In addition, Rothwell et al. reported 
that regular aspirin use reduced not only risk of distant 
metastasis [Hazard ratio (HR) 0.64, 95  % CI 0.48–0.84, 
p = 0.001] [17], but also cancer-related death [Odds ratio 
(OR) 0.79, 95 % CI 0.68–0.92, p = 0.003] [7]. Regarding 
the dose and the duration of aspirin, a meta-analysis of 
the five RCTs showed that aspirin at low dose (75–300 mg 
daily) reduced the 20-year incidence and mortality of 
CRC (incidence HR 0.75, 95  % CI 0.56–0.97, p  =  0.02; 
mortality HR 0.61, 95  % CI 0.43–0.87, p  =  0.005) and 
that the effects of aspirin increased with the duration of 
the treatment [6]. The results of recent meta-analysis are 
summarized in Table  1. Thus, aspirin could be effective 
for the prevention and/or the treatment of cancers. How-
ever, these findings are based on the results of observa-
tional studies and RCTs to evaluate the effects of aspirin 
on cardiovascular events. In addition, bleeding and gas-
trointestinal complications should be taken into consid-
eration in the use of aspirin. To investigate the efficacy 
and safety of aspirin, the Aspirin in Reducing Events in 
the Elderly (ASPREE; NCT01038583) study, a RCT, is 
ongoing. Currently aspirin should be administered only 
for patients with cardiovascular diseases, not for the pre-
vention of cancer.
Beta‑blockers and cancer
Previous experimental studies have demonstrated that 
chronic stress, depression and social isolation are associ-
ated with tumor progression [18–21]. As catecholamines 
such as norepinephrine and epinephrine are elevated 
under chronic stress and their effects are mainly medi-
ated through beta-adrenoreceptors, activation of beta-
adrenoreceptors by catecholamines is believed to play 
an important role in tumor progression. Indeed, the 
presence of beta-adrenoreceptors has been shown in the 
cell lines of breast cancer [22], pancreatic cancer [23], 
nasopharyngeal cancer [24] and ovarian cancer [25], and 
catecholamines significantly increased cell proliferation 
as well as cell migration in human cancer cell lines [26, 
27]. Furthermore, in a mouse model of ovarian cancer, 
beta-adrenergic stimulation not only increased angio-
genesis and tumor invasion through the cyclic adeno-
sine monophosphate (cAMP)-protein kinase A (PKA) 
pathway [25], but also prevented the cancer cells from 
apoptosis by activating focal adhesion kinase (FAK) [28]. 
Additionally, a recent study showed that beta-adrener-
gic activation increased distant metastasis by 30 times 
through M2 macrophage infiltration in a mouse model of 
breast cancer [29].
On the other hand, beta-blockers mainly block beta-
adrenoreceptors, and have been investigated as treatment 
Table 1 Anti-tumor effects of aspirin in recent meta-analyses




Type of cancer Main findings
González-Pérez et al. (2003) [13] 4, 5 and 11 Any Esophageal, gastric and breast 
cancer
Aspirin reduced the incidence 
of esophageal cancer (RR 
0·51, 95 % CI 0.38–0.69), 
gastric cancer (RR 0.73, 
0.63–0.84) and breast cancer 
(RR 0.77, 0.69–0.86), derived 
from four, five and eleven 
studies respectively
Flossmann et al. (2007) [12] 2 (5061) 300< CRC Aspirin reduced the incidence 
of CRC (HR 0.74, 95 % CI 
0.56–0.97, p = 0.02)
Rothwell et al. (2010) [6] 5 75–300 CRC Low-dose aspirin reduced 
the 20-year incidence and 
mortality of CRC (incidence 
HR 0.75, 95 % CI 0.56–0.97, 
p = 0.02; mortality HR 0.61, 
95 % CI 0.43–0.87, p = 0.005)
Rothwell et al. (2011) [7] 8 75< Any Regular aspirin use reduced 
cancer-related death (OR 
0.79, 95 % CI 0.68–0.92, 
p = 0.003). Therapeutic 
effects increased with dura-
tion of aspirin use
Rothwell et al. (2012) [17] 5 75< Any Regular aspirin use reduced 
the risk of distant metastasis 
(HR 0.64, 95 % CI 0.48–0.84, 
p = 0.001)
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for malignancies as well as cardiovascular diseases. Gen-
erally prescribed beta-blockers are classified into three 
types depending on selectivity of receptor subtypes, 
beta-1 selective beta-blockers such as bisoprolol, non-
selective beta-blockers (NSBB) such as propranolol and 
nadolol, and alpha- and beta-blockers such as carvedilol, 
which block beta-1, all types of, and alpha- and beta-
adrenoreceptors respectively. All of these beta-blockers 
are widely used for the treatment of heart failure, hyper-
tension, ischemic heart disease and arrhythmias in the 
cardiovascular field. A number of experimental studies 
have also shown the anti-tumor effects of beta-blockers. 
In human cancer cell lines, catecholamine-induced pro-
liferation and migration were inhibited by NSBB [26, 
27], and enhanced invasiveness [30] and activated FAK 
by catecholamine were completely blocked by proprano-
lol in a mouse model of ovarian cancer [28]. The action 
mechanisms of beta-blockers in tumor cells described 
above are currently proposed, as shown in Fig. 2. Moreo-
ver, in a mouse model of breast cancer, propranolol coun-
teracted catecholamine-induced metastasis to distant 
tissues through M2 macrophage infiltration [29], which 
indicates the importance of beta-adrenergic signaling in 
M2 macrophage. Interestingly, a recent publication dem-
onstrated that bisoprolol improved cardiac function and 
survival in a dose-dependent manner in rats with cancer 
cachexia, suggesting the favorable effects of beta-blockers 
in the terminal stage of cancer [31].
In clinical settings, several epidemiological studies 
have examined the potential effect of beta-blockers on 
the incidence and the outcome of cancer. The results 
have been inconsistent [32–37], as shown in Table 2, but 
some of them demonstrated that the use of beta-blockers 
was associated with improved overall survival in patients 
with certain types of cancer such as breast cancer (HR 
0.19, 95  % CI 0.06–0.60) [32], ovarian cancer (HR 0.54, 
95 % CI 0.31–0.94, p = 0.02) [33] and non-small cell lung 
carcinoma (HR 0.78, 95 % CI 0.63–0.97, p =  0.02) [34]. 
In addition, a recent meta-analysis of 12 clinical studies 
have shown that beta-blocker usage was associated with 
significantly improved overall survival (HR 0.79, 95  % 
CI 0.67–0.93, p = 0.004) [38]. Beta-blockers appeared to 
have a greater effect in patients with early-stage cancer 
or cancer treated with primary surgery than those with 
late-stage cancer or cancer treated without primary sur-
gery [38].
Thus, experimental and clinical evidences have indi-
cated the efficacy of beta-blockers for the treatment of 
cancer. Although there are no clinical trials to clarify 
it prospectively, to confirm these promising effects of 
Beta-blockers













Fig. 2 Putative mechanisms of action of beta-blockers in preventing tumor progression. Catecholamines are elevated under chronic stress and 
bind to beta-adrenoreceptors, resulting in activation of cAMP-PKA pathway and FAK, which accelerates tumor angiogenesis and invasion, and 
prevents cancer cells from apoptosis respectively. Beta-blockers blocks beta-adrenoreceptors, so that they are believed to suppress tumor growth 
and invasion. cAMP cyclic AMP, FAK protein kinase A, FAK focal adhesion kinase
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beta-blockers on cancer, two RCTs are ongoing to inves-
tigate the preventive role of beta-blockers in patients 
with breast cancer (NCT 00502684) and CRC (NCT 
00888797) undergoing surgery with curative intent.
ACE inhibitors, ARBs and cancer
Angiotensin II promotes vasoconstriction and sodium 
reabsorption via angiotensin II type 1 (AT1) recep-
tors in the renin-angiotensin system (RAS), resulting 
in increased blood pressure. Both of ACE inhibitors 
and ARBs, agents blocking RAS, are widely used in the 
cardiovascular fields for the treatment of heart failure, 
hypertension and old myocardial infarction. In addition 
to the systemic RAS, recently much attention has been 
paid to the existence of the local RAS in tumor cells. 
Indeed, AT1 receptors have been identified in various 
types of human cancer, such as renal cell carcinoma [39], 
laryngeal carcinoma [40], pancreatic cancer [41], ovar-
ian cancer [42], breast cancer [43], melanoma [44], and 
intrahepatic cholangiocarcinoma [45]. Moreover, immu-
nohistochemical analysis  showed co-localization of AT1 
receptor and vascular endothelial growth factor (VEGF), 
a major angiogenic protein, in pancreatic cancer cells 
[46], and expression of AT1 receptor was detected more 
frequently in high-grade invasive ovarian cancer than in 
benign ovarian tumor, and was positively correlated with 
expression of VEGF [42]. Administration of angiotensin 
II upregulated VEGF [42, 43, 46] and increased tumor 
angiogenesis [42], tumor growth [45], and tumor inva-
siveness [42]. Thus, these findings suggested that the local 
RAS controlled VEGF and tumor progression, and then 
blockade of the local RAS has been noted as a promising 
strategy for the treatment of cancer. Indeed, ACE inhibi-
tors suppressed VEGF expression, VEGF-induced angio-
genesis and tumor growth [47, 48] and ARBs also showed 
similar effects in certain cancer cell lines and animal can-
cer models [41–43, 45, 46]. Proposed action mechanisms 
are presented in Fig. 3.
In 1998, an observational study first demonstrated 
that hypertensive patients taking ACE inhibitors had 
a reduced cancer risk compared with patients in the 
control group (RR 0.72, 95  % CI 0.55–0.92) [49]. How-
ever, following clinical studies failed to show the favora-
ble effects of ACE inhibitors on cancer risk or outcome 
[50–54]. For example, Lindholm et  al. also investigated 
a protective role of ACE inhibitors for cancer in elderly 
patients with hypertension. In this study, ACE inhibitor 
usage was not associated with decreased risk of new can-
cer occurrence (standardized incidence ratio 0.99, 95  % 
CI 0.86–1.13) [52]. Furthermore, in 2010 a meta-analy-
sis of five RCTs revealed that the use of ARBs increased 
cancer risk (RR 1.08, 95 % CI 1.01–1.16) [55]. However, 
Table 2 Anti-tumor effects of beta-blockers in recent clinical studies
Authors (year), reference Number of patients  
taking beta‑blockers
Type of cancer Main findings
Fryzek et al. (2006) [155] NA Breast cancer The use of beta-blockers was not associated 
the risk of breast cancer (RR 1.07, 95 % CI 
074–1.56)
Assimes et al. (2008) [156] 1788 Any Beta-blockers significantly reduced the risk 
of cancer (OR 0.9, 95 % CI 0.85–0.96)
Powe et al. (2010) [157] 43 Breast cancer Patients taking beta-blockers had a 57 % 
reduced risk of metastasis (Hazard ratio 
0.43, 95 % CI 0.20–0.93)
Barron et al. (2011) [32] 70 Breast cancer Propranolol reduced cancer-related mortal-
ity (HR 0.19, 95 % CI 0.06–0.60)
Ganz et al. (2011) [36] 204 Breast cancer Beta-blocker usage was not associated with 
improved overall survival (HR 1.04, 95 % CI 
0.72–1.51)
Lemeshow et al. (2011) [37] 275 Melanoma Beta-blockers reduced all-cause mortality 
(HR 0.81, 95 % CI 0.67–0.97)
Diaz et al. (2012) [33] 23 Ovarian cancer Beta-blockers improved overall survival (HR 
0.54, 95 % CI 0.31–0.94, p = 0.02)
Wang et al. (2013) [34] 155 Non-small cell lung carcinoma Beta-blockers improved overall survival (HR 
0.78, 95 % CI 0.63–0.97, p = 0.02)
Grytli et al. (2014) [35] 1115 Prostate carcinoma The use of beta-blockers was not associated 
with reduced all-cause mortality (HR 0.92, 
95 % CI 0.83–1.02)
Choi et al. (2014) [38] 6717 Any Beta-blocker usage was associated with 
significantly improved overall survival (HR 
0.79, 95 % CI 0.67–0.93, p = 0.004)
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subsequent several meta-analyses showed no significant 
association between the use of ARBs and new cancer 
risk [56, 57] (Table 3). Judging from the results of clinical 
studies, there is no reason to administer ACE inhibitors 
or ARBs for the prevention and/or treatment of cancer 
despite the favorable findings in experimental research. 
Further long-term prospective trials are needed.
Cardiac glycosides and cancer
Cardiac glycosides were originally derived from the 
foxglove. Two types of cardiac glycosides, digoxin and 
digitoxin, have been currently prescribed to treat heart 
failure or to reduce heart rate in the cardiovascular field, 
whereas the relationship between cardiac glycosides 
and cancer have been noted since Shiratori et  al. [58] 
reported the antiproliferative effect of cardiac glycosides 
in cancer cells in1967. Sodium- and potassium-activated 
adenosine triphosphatase (Na+-K+-ATPase), the primary 
target of cardiac glycosides, exports three sodium ions in 
exchange for two potassium ions using ATP as an energy 
source, thereby maintaining the cell membrane poten-
tial. Indeed, increased expression of Na+-K+-ATPase 
was found in gastric [59] and bladder cancer cells [60], 
and elevated Na+-K+-ATPase activity was observed in 
highly invasive human renal carcinoma cells [61]. Cardiac 
glycosides bind to Na+-K+-ATPase and disrupt its abili-
ties in tumor cells. Namely, cardiac glycosides decreased 
the membrane potential and increase intracellular Na+, 
which caused the induction of apoptosis in human can-
cer cells [62], and also increased intracellular Ca2+ in 
human prostate adenocarcinoma cells, resulting in acti-
vation of calcineurin and transcriptional upregulation of 














Fig. 3 Local RAS, ACE inhibitors and ARBS in tumor cells. In tumor 
cells, angiotensin II promotes VEGF production via AT1 receptor, 
resulting in increased angiogenesis. ACE inhibitors and ARBs attenu-
ate local RAS and reduce VEGF-dependent angiogenic signals in 
cancer
Table 3 Anti-tumor effects of ACE inhibitors or ARBs in recent clinical studies
Authors (year), reference Number of patients taking 
ACE inhibitors or ARBs
Medication Type of cancer Main findings
Ronquist et al. (2004) [54] 100 ACE inhibitors Prostate cancer Current use of ACE inhibitors was 
not associated with decreased 
risk of prostate cancer (OR 0.9, 
95 % CI 0.7–1.1)
Sjoberg et al. (2007) [53] 62 and 101 ACE inhibitors Esophageal and gastric cancer Current use of ACE inhibitors did 
not decrease the risk of esopha-
geal and gastric cancer
(OR 0.79, 95 % CI 0.60–1.05 for 
esophageal cancer; OR 1.11, 
95 % CI 0.88–1.39 for gastric 
cancer)
Sipahi et al. (2010) [55] 2510 ARB Any Patients taking ARBs had a sig-
nificantly increased risk of new 
cancer development (RR 1.08, 
95 % CI 1.01–1.15; p = 0.016)
Pasternak et al. (2011) [56] 3954 ARB Any ARB did not increase the risk 
of cancer (RR 0.99, 95 % CI 
0.95–1.03)
The ARB Trialists Collaboration  
(2011) [57]
4549 ARB Any There was no association 
between ARB usage and cancer 
incidence (OR 1.00, 95 % CI 
0.95–1.04)
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mechanisms of cardiac glycosides such as suppression 
nuclear factor-kappaB [64] and inhibition of DNA topoi-
somerase II [65] were also shown to induce apoptosis in 
tumor cells (Fig. 4). The complex mechanism in cardiac 
glycoside-induced apoptosis has been already well docu-
mented [66–68].
In clinical settings, there were several studies evaluat-
ing the effects of cardiac glycosides on the development 
and progression of cancer. Early observational studies 
showed that the use of cardiac glycosides reduced the 
rate of recurrence and the malignant grade of breast can-
cer [69, 70] and a subsequent 20-year follow-up revealed 
that patients with cardiac glycosides had a significantly 
lower mortality rate (6  %) than those without cardiac 
glycosides (34  %) [71]. These findings seemed to indi-
cate the anti-tumor effect of cardiac glycosides, but the 
results from recent reports have been inconsistent with 
them. In 2001, a large cohort study (n = 9271) revealed 
that patients taking cardiac glycosides had a higher inci-
dence of cancer compared with controls [72]. Moreo-
ver, the use of cardiac glycosides was associated with an 
increased risk of invasive breast cancer (RR 1.30, 95 % CI 
1.14–1.48) among post-menopausal women [73] and the 
incidence of estrogen receptor-positive breast cancer was 
significantly higher than that of estrogen receptor-neg-
ative breast cancer in women taking cardiac glycosides 
[74]. Cardiac glycosides also increased the risk of corpus 
uteri cancer (RR 1.48, 95  % CI 1.32–1.65), whereas did 
not affect the incidence of ovary cancer (RR 1.06, 95  % 
CI 0.92–1.22) and cervix cancer (RR 1.00, 95 % CI 0.79–
1.25) [75] and reduced the risk of prostate cancer (RR 
0.76, 95  % CI 0.61–0.95) [76] (Table  4). These findings 
suggest that the estrogenic effect of cardiac glycosides 
might play an important role in inhibiting cancer, but 
further experimental studies and RCTs setting cancer-
related events as primary endpoints should be performed 
to confirm this hypothesis.
Statins and cancer
Statins, competitive inhibitors of 3-hydroxy-3-meth-
ylglutaryl-coenzyme A reductase, block the formation 
of mevalonate in the mevalonate pathway to synthesize 
cholesterol in liver and are commonly administered for 
the treatment of hyperlipidemia and the secondary pre-
vention of atherosclerotic diseases such as myocardial 
infarction and ischemic stroke. Geranylgeranyl pyroph-
osphate (GGPP) and farnesyl pyrophosphate (FPP) are 
downstream products of the mevalonate pathway and 
used as substrates in protein prenylation, which is essen-
tial for localization of proteins in cell membranes [77]. As 
GGPP and FPP are also inhibited by statins, it has been 
proposed that statins could cause apoptosis in tumor 
cells (Fig.  5). Indeed, experimental studies have shown 
that statins suppressed proliferation in multiple human 
cancer cell lines through this inhibitory activity [78–80]. 
Despite this promising anti-tumor effect of statins, the 
results of clinical studies are controversial. Initial clini-
cal trials showed that statins were associated with a sig-
nificant reduction in overall cancer incidence [81, 82]. 
Some subsequent meta-analyses have demonstrated 
that statins significantly reduced the risk of prostate 
[83], esophageal [84] and gastric cancer [85], while other 
recent meta-analyses failed to show benefits of statins in 
cancer-associated mortality [86], and in the risk of lung 
[87] and skin cancer [88]. The effects of statins on can-
cer in recently published meta-analyses are presented in 
Table 5. On the other hand, statins enhanced the efficacy 
of treatment in acute myeloid leukemia [89] and hepa-
tocellular carcinoma [90], when combined with chemo-
therapeutic agents. Further clinical investigation should 
be performed, since in most of clinical studies to inves-
tigate the role of statins, the primary endpoint was not 
set on cancer-related events and the observation period 
was not long enough to observe the development and/or 
prevention of cancer.
Repurposing of cardiovascular drugs 
in pathological conditions other tan cancer
Propranolol and infantile hemangioma
The efficacy of oral propranolol for infantile heman-
gioma was first reported in 2008 [91]. Several clinical 














Fig. 4 Cardiac glycoside-induced apoptosis in tumor cells. Cardiac 
glycosides bind to Na+-K+-ATPase and decrease the membrane 
potential and increase intracellular Na+ and Ca++ in certain human 
cancer cell lines, resulting in activation of calcineurin and transcrip-
tional upregulation of Fas ligand. Cardiac glycosides also suppressthe 
expression of nuclear factor-kappaB and inhibit DNA topoisomerase 
II. All of these activities induce apoptosis in human cancer cells
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revealed that infantile hemangioma regressed with the 
treatment of propranolol. Furthermore, in 2015, a large-
scale RCT showed that propranolol at a dose of 3  mg 
per kg for 6  months was well-tolerated and effective in 
the treatment of infantile hemangioma [97]. At present, 
propranolol is regarded as a first-line therapy for infantile 
hemangioma, though there is room for further research 
into duration or regimen of propranolol.
Beta‑blockers and migraine
The efficacy of beta-blockers for the prevention of 
migraine has been evaluated in RCTs. A controlled 
double-blind trial showed that propranolol was more 
efficacious than placebo and as efficacious as cyprohep-
tadine in reducing frequency, duration and severity of 
migraine attacks [98]. Moreover, the efficacy of combi-
nation of propranolol and cyproheptadine was greater 
than that of propranolol or cyproheptadine alone. Sub-
sequently, another controlled double blind trial revealed 
the more potent effect of metoprolol for the prevention 
of migraine attacks than aspirin [99]. In this study, treat-
ment effectiveness was defined as a 50  % decrease in 
the rate of migraine attacks and the response rate was 
Table 4 Relationship between cardiac glycosides and the incidence of cancer in recent clinical studies
Authors (year), reference Number of patients  
taking cardiac glycosides
Medication Type of cancer Main findings
Haux et al. (2001) [72] 9271 Digitoxin Any Digitoxin use increased the risk of cancer (SIR 
1.27, 95 % CI 1.18–1.37). Plasma digitoxin 
levels were negatively correlated with the 
risk of cancer
Ahern et al. (2008) [73] 2890 Digoxin Breast cancer Digoxin use was associated with the 
increased risk of breast cancer (OR 1.30, 
95 % CI 1.14–1.48). The risk was positively 
correlated with the duration of digoxin 
exposure (OR for 7–18 years of digoxin use 
1.39, 95 % CI 1.10–1.74)
Biggar et al. (2011) [74] 104,648 Digoxin Breast cancer Current digoxin use increased the risk of 
breast cancer (RR, 1.39; 95 % CI, 1.32–1.46). 
In digoxin users, the risk was higher for 
ER-positive breast cancers (RR, 1.35; 95 % 
CI, 1.26–1.45) than for ER-negative breast 
cancers (RR, 1.20; 95 % CI, 1.03–1.40)
Biggar et al. (2012) [75] 104,648 Digoxin Corpus uteri cancer Current digoxin use increased the risk of cor-
pus uteri cancer (RR 1.48, 95 % CI 1.32–1.65). 
(RR 1.06, 95 % CI 0.92–1.22) (RR 1.00, 95 % 
CI 0.79–1.25)
Biggar et al. (2012) [75] 104,648 Digoxin Ovary cancer Current digoxin use increased the risk of 
ovary cancer (RR 1.06, 95 % CI 0.92–1.22)
Biggar et al. (2012) [75] 104,648 Digoxin Cervix cancer Current digoxin use increased the risk of 
cervix cancer (RR 1.00, 95 % CI 0.79–1.25)
Platz et al. (2011) [76] 936 Digoxin Prostate cancer Current digoxin use decreased the risk of 











Fig. 5 Effects of statins on mevalonate pathway in tumor cells. 
Downstream products in the mevalonate pathway such as geranylge-
ranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) are 
substrates in protein prenylation. By inhibiting the formation of GGPP 
and FPP, statins exert anti-proliferatic activity in tumor cells
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45.2 % in metoprolol group and 29.6 % in aspirin group 
respectively. In the current guidelines, propranolol and 
metoprolol are listed up as effective medications for the 
treatment of migraine [100].
Beta‑blockers and cirrhosis
In patients with cirrhosis, portal hypertension gradually 
develops, leading to variceal bleeding, hepatic encepha-
lopathy, ascites, spontaneous bacterial translocation, 
hepatorenal syndrome. They have hyperdynamic cir-
culatory abnormalities, such as an increased cardiac 
output and a decreased peripheral vascular resistance. 
As a result, sympathetic nervous system is activated in 
this condition. To counteract these abnormalities and 
reduce portal pressure, NSBB is regarded as effective 
[101]. Selective beta-1 antagonists were less beneficial 
for the treatment of cirrhosis [102, 103], which indi-
cates the importance of both beta-1 and beta-2 adren-
ergic pathways. Recently, carvedilol has been noted as 
a promising medication for portal hypertension due to 
its anti-alpha-1 adrenergic activity, which decreases the 
hepatic vascular resistance, in addition to the beta-block-
ing activities [104].
In 1981, Lebre et al. first reported the effects of NSBB 
on the secondary prevention of variceal bleeding in 
patients with cirrhosis. Since then, many clinical stud-
ies have been performed to examine the role of NSBB 
in patients with chronic liver disease, cirrhosis and por-
tal hypertension. A meta-analysis of 12 RCTs (n = 769) 
demonstrated that the beta-blocker use reduced the rate 
of recurrent bleeding and mortality compared to pla-
cebo [105]. There is no significant difference between 
beta-blocker alone and the combination of beta-blocker 
and nitrate, despite the previous findings indicating the 
effectiveness of nitrate for the treatment of cirrhosis 
[106]. In a 2012 meta-analysis, combining NSBB and 
endoscopic variceal ligation resulted in less recurrent 
bleeding than either treatment alone [107].
In addition, the use of NSBBs has been considered to 
be effective for the primary prophylaxis as well as the 
secondary prophylaxis. A meta-analysis demonstrated 
that NSBB decreased variceal bleeding and mortality in 
patients with cirrhosis without previous gastrointestinal 
bleeding [108]. The current guidelines for the manage-
ment of portal hypertension, Baveno VI, also recommend 
that patients with high-risk small varices or large/
medium varices should receive NSBB, if not contradic-
tory, or endoscopic variceal ligation for the primary pre-
vention of variceal bleeding [109].
On the other hand, there are few studies to investigate 
the role of NSBB to prevent the formation of varices. 
Groszmann et al. [110] demonstrated that NSBB did not 
prevent the new development of varices in patients with 
cirrhosis and portal hypertension without varices. The 
use of NSBB for the pre-primary prophylaxis is not rec-
ommended in the current guidelines [109].
In addition, it would be noted that an observational 
study showed the harmful effect of NSBB in patients 
with advanced cirrhosis and refractory ascites. In this 
study, the use of NSBB was associated with significantly 
poor 1-year survival compared with control (19 vs 64 %, 
p  <  0.0001) [111]. However, further studies should be 
performed to evaluate the efficacy and safety of NSBB in 
this population.
Table 5 Effect of statins on cancer in recent meta-analyses
Authors (year), refer‑
ence
Number of studies Type of cancer Main findings
Bansal et al. (2012) [83] 15 cohort and 12 case–control studies Prostate cancer Statins decreased the risk of prostate cancer (RR 
0.93, 95 % CI 0.30–0.86) and advanced prostate 
cancer (RR 0.80, 95 % CI 0.70–0.90)
Singh et al. (2013) [84] 13 studies (including a post hoc analysis of 22 
RCTs)
Esophageal cancer Statins reduced the risk of esophageal cancer (OR 
0.72 95 % CI 0.60–0.86)
Wu et al. (2013) [85] 3 post hoc analyses of 26 RCTs and 8  
observational studies
Gastric cancer Statin use was associated with a decreased risk of 
gastric cancer (RR 0.73, 95 % CI 0.58–0.93)
Emberson et al. (2012) 
[86]
27 RCTs Any Statins did not reduce the incidence of, or mortality 
from, any type of cancer (RR 1.00, 95 % CI 0.96–
1.05 for incidence; RR 1.00, 95 % CI 0.93–1.08)
Tan et al. (2013) [87] 5 RCTs, 7 cohort and 7 case–control studies Lung cancer Statin did not decrease the risk of lung cancer 
either among RCTs (RR 0.91, 95 % CI 0.76–1.09), 
cohort studies (RR 0.94, 95 % CI 0.82–1.07) and 
case–control studies (RR 0.82, 95 % CI 0.57–1.16)
Zhang et al. (2014) [88] 29 studies (including a post hoc analysis of 8 
RCTs)
Skin cancer Statins did not reduce the risk of skin cancer 
among melanoma (RR 0.94, 95 % CI 0.85–1.04) 
or non-melanoma skin cancer (RR 1.03, 95 % CI 
0.90–1.19)
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Beta‑blockers and osteoporosis
Previous experimental studies revealed that beta-adren-
oreceptors are expressed on osteoblastic and osteoclastic 
cells and that a beta agonist stimulates osteoblasts result-
ing in bone resorption [112]. These findings supported 
that a beta agonist decreased bone mass, while a beta 
antagonist increased bone mass in mice [113].
Recently the importance of sympathetic nervous sys-
tem in bone remodeling has been focused on. Ducy et al. 
[114] demonstrated that intracerebroventricular infu-
sion of leptin inhibited bone formation and decreased 
bone mass in mice, which indicated the central role 
of leptin in bone remodeling. Furthermore, Takeda 
et  al. [113] showed that the effect of leptin was medi-
ated by beta2-adrenoreceptors on osteoblasts. Namely, 
blockade of beta2-adrenoreceptors caused bone forma-
tion [113], while stimulation of beta2-adrenoreceptors 
resulted in bone resorption [115]. These findings sug-
gest that beta-blockers could be a therapeutic option for 
osteoporosis.
There are numerous clinical studies which evaluated 
the effects of beta-blockers on the risk of osteoporo-
tic fractures in humans. The results are inconsistent, 
however recent meta-analyses have shown that beta-
blockers reduced the risk of fracture by approximately 
15 %, independent of gender, fracture site and dose [116, 
117]. The most recent meta-analysis (n  =  1,644,570) 
has demonstrated that beta-blocker use was associated 
with a significantly lower risk of fractures (16 studies, 
RE pooled ES = 0.86, 95 % CI 0.78–0.93) [118]. Intrigu-
ingly, beta1-selective beta-blockers significantly reduced 
the risk of any fracture compared with NSBB (6 studies, 
RE pooled ES  =  0.82, 95  % CI 0.69–0.97) [118]. These 
findings do not support the proposed mechanism in 
which bone formation is promoted by the blockade of 
beta2-adrenoreceptor.
Additionally, hemodynamic alteration with beta-
blockers might affect the incidence of falls and fractures. 
Namely, anti-arrhythmic actions could prevent subjects, 
especially elderly people, from a fall, while (orthos-
tatic) hypotension and/or bradycardia could make them 
injured in a fall, sometimes a hip-fracture. Although 
findings of clinical studies have been inconsistent with 
regard to beta-blockers and risk of falls, there are no evi-
dence that beta-blockers increased the incidence of falls 
[119–121].
Collectively, the roles of beta-adrenoreceptors in bone 
remodeling are complex and further studies are needed 
to clarify them. Asbeta-blockers appear to reduce the risk 
of osteoporotic fracture in clinical settings, RCTs should 
be performed to evaluate the efficacy and safety of beta-
blockers in this condition.
Losartan and Marfan’s syndrome
Marfan’s syndrome is caused by mutations in the gene 
encoding fibrillin-1 [122], which regulates the transform-
ing growth factor beta (TGF-beta) signaling pathway. In 
a mouse model of Marfan’s syndrome, fibrillin-1 defi-
ciency was associated with increased TGF-beta signaling 
[123, 124], which is thought to contributes to the devel-
opment of aortic aneurysm. In 2006, Habashi et al. [125] 
showed that losartan, one of the ARBs, suppressed the 
excessive TGF-beta signaling and prevented the forma-
tion of aortic aneurysm in fibrillin-1 deficient mice. In 
this study, the losartan treatment was significantly effi-
cacious for the prevention of aortic aneurysm compared 
with the propranolol treatment [125]. Subsequently, the 
effect of losartan was examined in patients with Marfan’s 
syndrome. Two small cohort studies demonstrated that 
losartan significantly slowed the rate of aortic growth in 
pediatric patients with Marfan’s syndrome [126, 127] and 
in a RCT, aortic dilation rate was reduced by losartan in 
adult patients with Marfan’s syndrome [128]. However, 
a recent RCT showed that there was no significant dif-
ference in the progression of aortic diameter between 
losartan-treated and atenolol-treated patients with Mar-
fan’s syndrome [129]. Further experimental and clinical 
investigation should be performed, though the suppres-
sion of enhanced TGF-beta signaling seems important in 
this condition.
Preoperative statins and perioperative risk
Experimental research has demonstrated that statins 
improve endothelial function, attenuate vascular and 
myocardial remodeling, inhibit vascular inflammation 
and oxidation, and stabilize atherosclerotic plaques as 
pleiotropic effects beyond cholesterol lowering [130], 
which are expected to prevent plaque rupture and subse-
quent cardiovascular events in the perioperative period. 
Indeed, several observational studies have suggested that 
statin use decreased short-term mortality and myocar-
dial infarction [131–134]. In addition, a RCT showed that 
atorvastatin was associated a significant reduction in the 
incidence of cardiac events at 6  months follow-up after 
vascular surgery [135]. In the light of these findings, both 
the current ESC/ESA and ACC/AHA guidelines give 
a class I recommendation for continuing perioperative 
statins [136, 137]. In statin-naïve patients, two meta-anal-
yses showed the preventive effect of statins on periop-
erative myocardial infarction and death, which allows a 
class IIa recommendation in the ESC/ESA and ACC/
AHA guidelines for pre-operative initiation of statins 
for patients undergoing vascular surgery [136, 137]. In 
non-cardiac surgery, evidence is insufficient, but statins 
appear more beneficial in patients with accumulated 
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cardiovascular risk and statins are often prescribed in 
such case in clinical practice.
Statin and contrast‑induced nephropathy
Contrast-induced nephropathy (CIN) is characterized 
by acute kidney injury, caused by contrast medium. To 
prevent CIN, there are limited strategies such as volume 
expansion, use of iso-osmolar contrast and less amount 
of contrast media. The pathophysiological mechanisms of 
CIN are not fully understood, but contrast media might 
cause renal vasoconstriction, oxidative stress, inflamma-
tion and direct tubular necrosis [138]. As statins improve 
endothelial function and exert anti-inflammatory and 
antioxidative properties as well as lower cholesterol 
[139–141], statins have been regarded as promising 
therapeutic approach. Experimental research suggested 
that statins ameliorated acute ischemic renal failure and 
prevented tubular necrosis in rats [142]. In clinical set-
ting, a recent meta-analysis seven RCTs showed that the 
use of high-dose statins significantly reduced the risk 
of CIN compared to that of low-dose statins or placebo 
(RR 0.51, 95 % CI 0.34–0.76) [143]. In addition, a large-
scale RCT, Novel Approaches for Preventing or Limiting 
Events (NAPLES) II trial, showed that a single high-dose 
of atorvastatin significantly reduced the incidence of CIN 
compared with placebo in patients with chronic kidney 
disease undergoing elective coronary angiography (OR 
0.22, 95 % CI 0.07–0.22) [144]. Another large-scale RCT, 
protective effect of rosuvastatin and antiplatelet therapy 
on contrast-induced acute kidney injury and myocar-
dial damage in patients with acute coronary syndrome 
(PRATO-ACS) trial, randomly assigned patients with 
acute coronary syndrome undergoing an early coronary 
angiography to rosuvastatin or placebo, and revealed that 
high-dose rosuvastatin prevented CIN (OR 0.38, 95 % CI 
0.20–0.71) [145]. These findings support the use of statins 
for the prevention of CIN in coronary angiography, 
while future research should investigate effect of statins 
in other examinations or treatments such as computed 
tomography, as well as timing of initiation and duration 
of statin treatment.
Minoxidil and androgenic alopecia
Oral minoxidil had been originally developed as an anti-
hypertensive drug in 1960s and was reported to cause 
hypertrichosis as well as an antihypertensive effect in 
1970s/80s [146, 147], which led to the research of topi-
cal minoxidil for the treatment of alopecia [148]. Several 
mechanisms how minoxidil improves alopecia have been 
proposed. Minoxidil stimulates cutaneous blood flow 
through local vasodilatory effect in human scalps [149], 
up-regulates the expression of VEGF in human hair der-
mal papilla cells [150], and prolongs the anagen period of 
hair follicle through the opening of potassium channels 
[151]. All of these actions could help to promote or main-
tain hair growth.
In male alopecia, 2 and 5  % minoxidil solutions have 
been approved and the 5  % solution has shown higher 
efficacy than the 2  % solution [152]. Recently, the foam 
type has been newly developed, and the effect of 5  % 
minoxidil foam has been comparable to the 5 % minoxi-
dil solution. The minoxidil treatment during 5 years has 
shown the continuous efficacy [153], while the thera-
peutic effect has disappeared in 24  weeks after dis-
continuation [154]. In female alopecia, only the 2  % 
minoxidil solution or foam are currently used. As higher 
dose seems to show higher efficacy both in males and 
females, further clinical studies might allow higher dose 
to be approved.
Conclusions
A number of studies have demonstrated anti-tumor 
activities of cardiovascular drugs in tumor cells and ani-
mal models, while findings of clinical trials, including 
large-scale RCTs, have often been inconsistent with those 
of preclinical studies or other clinical trials. Meta-analy-
sis might some contributions to this ‘dissociation’. Meta-
analysis is convenient and widely used, while we should 
pay appropriate attention to the fact that meta-analysis is 
hard to gather detailed data such as patient characteris-
tics and easily biased. It could be important to consider 
cancer type, cancer stage and patient characteristics such 
as age, sex, body mass index in evaluating cancer. Regard-
ing aspirin and beta-blockers, RCTs are ongoing and the 
results are anticipated with great interest.
In the pathophysiological conditions other than cancer, 
some cardiovascular drugs have already obtained new 
indications, such as propranolol for infantile heman-
gioma, beta-blockers for migraine, and minoxidil for 
androgenic alopecia. Preoperative use of statins for peri-
operative risk reduction may be used for patients under-
going non-cardiovascular surgery.
Thus, based on the available knowledge and informa-
tion, it would be expected that unknown mechanisms of 
action of drugs are investigated by experimental studies 
and that clinical evidences are established by well-organ-
ized RCTs. Close link between experimental and clinical 
studies is essential.
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